Hepatitis C

Hepatitis C virus: cascade of care in infants and children

Hepatitis C virus: cascade of care in infants and children

By Dr. Laura Sauvé, Winnie Fu, Dr. Sofia Bartlett, Dr. Orlee Guttman, Dr. Chelsea Elwood, Dr. David Goldfarb, Dr. Neora Pick on August 19, 2024

Children perinatally exposed to hepatitis C virus (HCV) in pregnancy have a 5-11% chance of becoming infected with HCV. Data suggests that a high proportion of infants exposed to HCV may be lost to care in the current system in BC. We recommend interventions to help identify and treat babies and infants exposed to HCV.

World Hepatitis Day

Hepatitis C birth cohort testing

By Drs. Mel Krajden and Jim Gray on July 28, 2022

WHO observes July 28th as World Hepatitis Day and aims to eliminate Hepatitis B and C by 2030. The Pan-Canadian Sexually Transmitted and Blood-Borne Infections (STBBI) Framework for Action released in 2018 echoes this goal and calls for 80% of eligible people in Canada to receive hepatitis C treatment by 2030. In order to achieve these goals by 2030, high rates of testing and diagnosis are essential. New HCV therapies are well tolerated, require 8–12 weeks of treatment, are publicly funded in BC, and have cure rates of about 95%.

Use of non-invasive tests for liver fibrosis

Use of non-invasive tests for liver fibrosis

By Drs. Shirley Jiang and Hin Hin Ko on March 9, 2022

While liver biopsy is crucial in determining the stage of liver fibrosis in chronic liver disease, it is not the most accessible or appropriate test in most general practice settings. Non-invasive tests (NITs) for liver fibrosis, on the other hand, are more widely available and applicable to different liver conditions. NITs can be a useful tool in general practice to stratify high-risk patients who may require further investigations and referral to specialist care.

You too can help eliminate Hepatitis C by 2030

You too can help eliminate Hepatitis C by 2030

By Trana Hussaini Pharm D and Eric M. Yoshida MD FRCPC on November 13, 2019

For the first time, since the identification of hepatitis C virus, the goal of HCV elimination is a tangible and achievable target mainly due to the availability of highly efficacious and well tolerated DAA regimens.

Treating Hepatitis C – the future is now!

Treating Hepatitis C – the future is now!

By Dr. Eric Yoshida on July 18, 2011

This year, based on the phase III studies published in the New England Journal of Medicine, the FDA approved the new protease inhibitors, telapravir and boceprevir in combination with pegIFN and ribavirin for patients with HCV G1 infections.

Visit UBC CPD at ubccpd.ca

UBC CPD website

View all CPD learning activities: virtual, in-person and hybrid conferences, workshops, webinars, online modules, customized community courses, simulation hands-on courses, coaching, mentoring, personalized learning, recordings, and more.

Visit UBC CPD ↗

This field is for validation purposes and should be left unchanged.